Reach Us +1-947-333-4405


Editor - Glenn Simon Tillotson | Cempra Pharmaceuticals | 22467
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Indexed In
  • Index Copernicus
  • Google Scholar
  • Open J Gate
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • Euro Pub
Share This Page

Glenn Simon Tillotson

Glenn Simon Tillotson
Glenn Simon Tillotson
Cempra Pharmaceuticals


Dr. Glenn Simon Tillotson worked over 35 years in healthcare with almost 30 years in pharmaceuticals (R&D and Medical Affairs). He has completed his Bachelor of Science in Microbiology and Biochemistry from Liverpool Polytechnic, Liverpool, UK (1974-1978). In 1980 he received his Master of Science in Medicine from University of Manchester Medical School, Manchester, UK. Dr. Glenn Simon Tillotson was Visiting Distinguished Scientist of Public Health Research Institute in NYC (2001). In 2005, he has finished his Ph D from Richmond University, London. He worked as Fellow of Royal Society of Medicine, London, UK (2000), American College of Chest Physicians, Chicago (2006), International Society of Chemotherapy (2008) and Infectious Disease Society of America (2010). He received Alfred Soffer Award by American College of Chest Physicians for Editorial Excellence. Dr. Glenn Simon Tillotson has experience in drug research and development including pre-clinical studies, IND, NDA, MAA and product life cycle extension (sNDA). He had memberships of various societies. In 2014 and 2015, he worked as Scientific Advisory Board- Spero Pharmaceuticals, Cambridge MA and Scientific Advisory Board- Assembly BioSciences, NYC, respectively. Currently, Dr. Glenn Simon Tillotson working as Senior Vice President of Medical Affairs in Cempra Pharmaceuticals, Chapel Hill. He has demonstrated success in range of product development, product launches and life cycle management strategies, harnessed innovative communication strategies both externally and internally, developed several medical affairs teams both internationally and nationally and shown resourcefulness in business development activities. He served as Editorial Board and Reviewer for 24 different journals from 1991 to 2014). He has written 200 papers (>150 papers on PubMed), 5 book chapters. He edited e-book on Clostridium difficile, published in September 2013 by Future Medicine, London, UK.  Given >500 lectures to National, Regional or State conferences.

Research Interest

Glenn S Tillotson has over 30 years pharmaceutical experience in pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs. He has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin and several other agents. He is a SVP of Medical Affairs where he is preparing for the launch of solithromycin for community acquired bacterial pneumonia.